Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
NCT05597202 on ClinicalTrials.gov · last registry update 2023-05-09
A small phase 4 — 22 participants, against a typical 75. Its estimated completion date, March 2024, has passed with no update to the record. Primary outcome, as filed: Difference in coronary 68Ga-Dotatate uptake after treatment. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- UNKNOWN
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Sponsor type
- Other
- Enrollment
- 22
- Started
- 2023-01-01
- Primary completion
- 2024-03 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Difference in coronary 68Ga-Dotatate uptake after treatment.
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.